Background We performed a systematic overview of the cost-effectiveness analyses (CEAs)
comparing Non-insulin antidiabetic drugs (NIADs) with other NIADs for the treatment of type …

Purpose of review Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently
approved class of drugs (since 2012) for type 2 diabetes mellitus (T2DM), but their economic …

Aims The economic burden of diabetes is driven by the management of vascular
complications. Sodium–glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated …

Aim To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients
with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE …

Introduction The increasing financial burden associated with diabetes treatment presents a
challenge to healthcare systems worldwide. Recently, clinical guidelines have focussed on …

Objective Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce
the risk of cardiovascular complications, which largely drive diabetes' health and economic …

To jointly assess the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors
(SGLT2i) on cardiorenal outcomes and all-cause mortality in type 2 diabetes mellitus …

Purpose Agents that inhibit sodium glucose co-transporter 2 (SGLT2), including
canagliflozin and dapagliflozin, become available for the treatment of Chinese patients with …

Aims To compare cardio-renal outcomes and incurred direct medical costs of patients
initiating sodium glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 …

Disease burden in people with diabetes is mainly driven by long-term complications such as
cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of …